Main Street Financial Solutions’s Protalix BioTherapeutics PLX Stock Holding History

Main Street Financial Solutions’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$499K	Hold	214,100	–	–	0.03%	364
2026 Q1	$465K	Hold	214,100	–	–	0.03%	353
2025 Q4	$385K	Buy	214,100 +85,000	+66%	+$174K	0.03%	383
2025 Q3	$287K	Buy	+129,100	New	+$210K	0.02%	504

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Main Street Financial Solutions's PLX Position: Q2 2026 in Review

Main Street Financial Solutions held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 214,100 shares worth $499K. The position accounts for 0.03% of the portfolio, ranked #364.

Main Street Financial Solutions first reported a position in PLX in Q3 2025 and has held it in 4 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Main Street Financial Solutions held 214,100 shares of Protalix BioTherapeutics worth $499K as of Q2 2026.
Main Street Financial Solutions left its Protalix BioTherapeutics share count unchanged in Q2 2026.
Protalix BioTherapeutics made up 0.03% of Main Street Financial Solutions's portfolio in Q2 2026, its #364 holding.
Main Street Financial Solutions first reported a position in Protalix BioTherapeutics in Q3 2025 and has held it in 4 quarters since.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Main Street Financial Solutions's 13F filing for Q2 2026, filed 7 Aug 2026.